Agonistic activity of tamoxifen, a selective estrogen-receptor modulator (SERM), on arthritic ovariectomized mice

Braz J Med Biol Res. 2017 Nov 13;51(1):e6799. doi: 10.1590/1414-431X20176799.

Abstract

Arthritis is positively associated with the decline of sex hormones, especially estrogen. Tamoxifen (TMX) is a selective estrogen receptor modulator, possessing agonist or antagonistic activity in different tissues. Thus, the objective of this study was to investigate the effect of TMX on the zymosan-induced arthritis model. Female Swiss normal and ovariectomized (OVX) mice were divided into groups and treated for five days with TMX (0.3, 0.9 or 2.7 mg/kg) or 17-β-estradiol (E2, 50 µg/kg). On the fifth day, arthritis was induced and 4 h later, leukocyte migration into joint cavities was evaluated. The neutrophil migration in OVX animals, but not in normal mice, treated with TMX (all tested doses) was significantly decreased compared with mice that received the vehicle (P≤0.05). Similarly, this effect was also demonstrated in the E2-treated group. Therefore, the present study demonstrates that TMX presented agonist effects in inhibiting neutrophil migration and preventing arthritis progression in OVX mice.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Arthritis, Experimental / drug therapy*
  • Cell Migration Assays, Leukocyte
  • Cell Movement / drug effects
  • Disease Models, Animal
  • Estrogen Antagonists / pharmacology
  • Estrous Cycle / drug effects
  • Female
  • Mice
  • Neutrophils / drug effects
  • Organ Size / drug effects
  • Ovariectomy*
  • Random Allocation
  • Reproducibility of Results
  • Selective Estrogen Receptor Modulators / pharmacology*
  • Tamoxifen / pharmacology*
  • Time Factors
  • Treatment Outcome
  • Uterus / drug effects
  • Zymosan

Substances

  • Estrogen Antagonists
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Zymosan